MB
TECX

MPM BioImpact’s Tectonic Therapeutic TECX Stock Holding History

MPM BioImpact’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-53,993
Closed -$648K – 38
2023
Q1 		$648K Hold
53,993
– – 0.17% 30
2022
Q4 		$462K Hold
53,993
– – 0.12% 31
2022
Q3 		$416K Hold
53,993
– – 0.1% 37
2022
Q2 		$596K Hold
53,993
– – 0.17% 36
2022
Q1 		$855K Hold
53,993
– – 0.23% 36
2021
Q4 		$2.49M Sell
53,993
-17,829
-25% -$1.02M 0.45% 31
2021
Q3 		$4.81M Buy
+71,822
New +$5.89M 0.75% 27

Other funds holding TECX

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MPM BioImpact's TECX Position: Q2 2023 in Review

MPM BioImpact sold out of Tectonic Therapeutic (TECX) in Q2 2023, closing a stake of 53,993 shares — an estimated $648K sold.

MPM BioImpact first reported a position in TECX in Q3 2021 and held it in 7 quarters. The position peaked at $4.81M in Q3 2021. 40 funds tracked by Wall St. Rank hold TECX as of Q2 2023.

  • MPM BioImpact reported no remaining Tectonic Therapeutic position as of Q2 2023 after selling out during the quarter.
  • MPM BioImpact sold 53,993 Tectonic Therapeutic shares in Q2 2023, an estimated $648K.
  • MPM BioImpact first reported a position in Tectonic Therapeutic in Q3 2021 and held it in 7 quarters.
  • MPM BioImpact's Tectonic Therapeutic position peaked at $4.81M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q2 2023.

Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.